<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663713</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C05274</org_study_id>
    <nct_id>NCT02663713</nct_id>
  </id_info>
  <brief_title>A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction</brief_title>
  <acronym>ALTIC</acronym>
  <official_title>A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taken together the results from CHARISMA and PEGASUS-TIMI54, it appears that physicians may&#xD;
      consider extending beyond 1 year or reinitiating treatment with clopidogrel 75 mg od or&#xD;
      ticagrelor 60mg bid in patients with a prior MI and features of high ischemic and low&#xD;
      bleeding risk. Comparative clinical or pharmacodynamic studies, however, between clopidogrel&#xD;
      75 mg od and ticagrelor 60 mg bid in the chronic phase of stable post MI patients have not&#xD;
      been performed.&#xD;
&#xD;
      In a platelet substudy of PEGASUS-TIMI 54, 180 patients who had received &gt;4 weeks of study&#xD;
      medication had platelet reactivity assessment. Ticagrelor 60mg bid achieved high levels of&#xD;
      peak and trough platelet inhibition in nearly all patients, with similar consistency of&#xD;
      effect compared to 90mg bid. Platelet reactivity (PRU) was significantly reduced with&#xD;
      ticagrelor 60mg bid compared to placebo.&#xD;
&#xD;
      In light of this, we believe that a dedicated pharmacodynamic study of ticagrelor 60 bid mg&#xD;
      vs clopidogrel 75 mg od in a PEGASUS-like population would be informative for the practicing&#xD;
      clinician, thus setting the rationale for conducting this specifically designed&#xD;
      investigation.&#xD;
&#xD;
      This is a prospective, randomized, single blind, single center, crossover study. Eligible&#xD;
      patients undergoing P2Y12 receptor antagonist therapy before screening will undergo a 14-day&#xD;
      minimum washout period before randomization. Following screening/washout period (visit 1),&#xD;
      patients will be randomized (visit 2, time 0) in 1:1 fashion to either clopidogrel 75 mg od&#xD;
      or ticagrelor 60 mg bid. Following 14±2 days (visit 3) patients will receive alternate&#xD;
      treatment for additional 14 days (visit 4). Platelet reactivity assessment will be performed&#xD;
      with the VerifyNow P2Y12 reaction assay at time 0, prior to first study drug dose. At visit 3&#xD;
      platelet function will be assessed at 2-4 hours post dose and prior to crossover. At visit 4&#xD;
      also platelet function will be assessed at 2-4 hours post study drug post dose. All patients&#xD;
      will receive concomitant aspirin (100 mg/d) and standard secondary prevention medication.&#xD;
&#xD;
      The primary endpoint is the platelet reactivity measured in P2Y12 reaction units (PRU) at the&#xD;
      end of the 2 study periods (pre-crossover and post-crossover).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods (pre-crossover and post-crossover).</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• High platelet reactivity rate (defined as &gt;208 PRU) at the end of the 2 study periods</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• VerifyNow P2Y12 assay % inhibition, using the TRAP-induced (BASE channel) response at the end of the 2 study periods</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Renal Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 60 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 60mg twice daily</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 75 mg once daily</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Post-menopausal female (defined as absence of any vaginal bleeding for a year) or male&#xD;
             aged &gt;50 years&#xD;
&#xD;
          3. A spontaneous MI (ST or Non ST segment elevation) 1 to 3 years before enrolment. In&#xD;
             addition, at least one of the following high-risk features: age of 65 years or older,&#xD;
             diabetes mellitus requiring medication, a second prior spontaneous MI, multivessel&#xD;
             coronary artery disease, or non-end stage renal disease (estimated creatinine&#xD;
             clearance of &lt;60 ml per minute).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned use of a P2Y12 receptor antagonist, dipyridamole, cilostazol, or anticoagulant&#xD;
             therapy during the study period;&#xD;
&#xD;
          2. Known allergy, intolerance, hypersensitivity to ticagrelor or clopidogrel or any&#xD;
             excipients,&#xD;
&#xD;
          3. Active pathological bleeding, severe hepatic impairment, a bleeding disorder or a&#xD;
             history of an ischemic stroke or intracranial bleeding, a central nervous system&#xD;
             tumor, or an intracranial vascular abnormality;&#xD;
&#xD;
          4. Gastrointestinal bleeding within the previous 6 months or major surgery within the&#xD;
             previous 30 days;&#xD;
&#xD;
          5. Concomitant use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors (atazanavir,&#xD;
             clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir,&#xD;
             ritonavir, saquinavir, telithromycin and voriconazole, grapefruit juice over 1 litre&#xD;
             daily), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or&#xD;
             inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and&#xD;
             rifapentine).&#xD;
&#xD;
          6. Increased risk of bradycardic events (e.g. known sick sinus syndrome or third degree&#xD;
             AV block or previous documented syncope suspected to be due to bradycardia unless&#xD;
             treated with a pacemaker).&#xD;
&#xD;
          7. Inability to adhere to the follow-up requirements or any other reason or condition&#xD;
             that the investigator feels would place the patient at increased risk if the&#xD;
             investigational therapy is initiated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiology Department Patras University Hospital</name>
      <address>
        <city>Rio</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>MI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

